Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 26th Preview)
-
FDA approvals expanding immunotherapy use
The FDA expanded Gilead’s Trodelvy label into front-line triple-negative breast cancer (TNBC), giving TROP2 ADCs a new footing in first-line treatment. The update allows Trodelvy to be used in patients who are ineligible for PD-1/L1 inhibitors regardless of PD-L1 status, and in combination with Keytruda (pembrolizumab) for PD-L1-positive tumors meeting a CPS threshold of at least 10. The approval is backed by two Phase 3 programs. In Ascent-03, Trodelvy reduced the risk of progression or death by 38% versus chemotherapy in PD-(L)1 inhibitor–ineligible patients. In Ascent-04 (Keynote-D19), the Trodelvy plus Keytruda regimen improved progression-free survival by 35% versus Keytruda plus chemotherapy in PD-L1-positive disease. Clinicians now face a widened set of first-line sequencing options for TNBC patients, increasing competitive pressure on other first-line TROP2 ADC efforts. The label breadth may also influence trial enrollment strategies for next-generation TNBC combinations targeting PD-1/L1 pathways.
-
Drugmakers pursue regulatory paths after setbacks
Replimune’s oncolytic immunotherapy RP1 cleared an FDA acceptance hurdle for a third regulatory attempt in advanced melanoma, with a decision expected on or before Aug. 2. The FDA has also signaled an advisory committee meeting in late July as part of the resubmission package. RP1 has been rejected twice previously: first in July 2025 over the FDA’s view that the pivotal study did not qualify as an “adequate and well-controlled” investigation, then again in April when the agency said the data were insufficient to support substantial evidence of effectiveness. The resubmission followed leadership changes inside the FDA and a “collaborative dialogue” that aligned the company and regulator on a path forward. Replimune is pursuing accelerated approval for RP1 combined with Bristol Myers Squibb’s Opdivo (nivolumab) in patients with disease progression after prior PD-1 treatment—an approach that directly tests whether the updated evidence package can overcome prior evidentiary concerns.
-
AI-enabled target discovery for next-generation CAR-T
Researchers at the University of Pennsylvania unveiled an AI-assisted pipeline to nominate and validate CAR-T targets for solid tumors, spotlighting GPNMB as a multi-cancer candidate. The work, published in Cell, uses a human-in-the-loop framework that pairs large language models with single-cell RNA-seq datasets, then iteratively refines target shortlists for expert testing. The team applied the workflow to skin cancer datasets, filtering more than 10,000 potential antigens by tumor composition, tissue specificity, and CAR-T feasibility constraints. Multiple LLM runs (1,000 independent simulations) were used to reduce noise and hallucinations, resulting in a consensus list that was experimentally evaluated. In preclinical mouse models, GPNMB-directed CAR-T eliminated tumors not only in melanoma but also in models of monoblastic leukemia and colorectal adenocarcinoma, supporting broader therapeutic exploration beyond skin cancer. The approach targets a core bottleneck in solid-tumor CAR-T development: finding antigens that balance selectivity and clinical tractability.
-
Regenerative medicine and diagnostic modernization funding
ARPA-H committed $90.7 million over four years through its Making Obstetrics Care Smart (MOCS) program to speed point-of-care diagnostics and monitoring approaches designed to improve childbirth safety. The funding begins June 16 and targets interventions to identify patients at high risk for fetal hypoxia—reduced fetal oxygen delivery—during pregnancy and labor. Projects include a UC San Diego-led team developing a point-of-care blood test using fetal and maternal proteins, nucleic acids, and extracellular vesicles, with industry collaborators Sera Prognostics and Allegro MicroSystems supporting biomarker discovery and evaluation. Separately, investigators at the Wyss Institute at Harvard University (Jim Collins) plan a microfluidic device to capture fetal/placental extracellular vesicles and analyze mRNA signatures to predict fetal hypoxia risk. The program also supports an autonomous wearable ultrasound approach from a UNC Charlotte team to assess placental health during labor without a dedicated ultrasound technician, alongside noninvasive wireless monitoring concepts integrating fetal heart rate, contraction metrics, and AI-driven analytics to estimate real-time oxygenation.
-
Big Tech M&A for life science tools and diagnostics
Merck KGaA agreed to acquire Bio-Techne in an $11.3 billion deal, positioning the company to expand its life sciences tools, analytics, and workflows across discovery and advanced therapeutics. The acquisition includes Bio-Techne assets spanning recombinant proteins, antibodies, immunoassays, and automated systems such as ProteinSimple, along with RNAscope multiplex RNA in situ hybridization technology. Merck KGaA will also gain exposure to cell culture device manufacturing through Wilson Wolf, which Bio-Techne is in the process of acquiring. Management framed the combination as accelerating platformed capabilities across multi-omics, spatial biology, and cell and gene therapy-enabling workflows. The price represents a 36% premium to Bio-Techne’s one-month volume-weighted average trading price and is funded through a mix of existing cash and new debt. Merck KGaA expects cost synergies of roughly €140 million by year three post-close and targets closing by late 2026 or early 2027.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.